April 25 (Reuters) - Biotech company Acuitas Therapeutics and Germany-based CureVac (5CV.DE), opens new tab have settled Acuitas' lawsuit demanding credit for inventions related to COVID-19 vaccines, ...
FARGO, N.D. & VANCOUVER, British Columbia--(BUSINESS WIRE)--Aldevron, a leading global manufacturer of DNA, RNA, and proteins used in cell and gene therapies and vaccine development, today announced ...
Bayer is partnering with Acuitas Therapeutics, the biotech that developed the lipid nanoparticle (LNP) technology behind Pfizer and BioNTech’s COVID-19 vaccine. The pact will give Bayer access to ...
Associate Professor of Pathology - Johns Hopkins University School of Medicine and Director of the Medical Bacteriology and Infectious Disease Sequencing Laboratories - Johns Hopkins Hospital Recently ...
ReciBioPharm, the advanced and emerging therapies business unit within Recipharm, Acuitas Therapeutics report that they are taking their partnership to the next level. The companies say they ready to ...
Acuitas’ LNP enabled delivery of three doses of a personalized CRISPR therapy with no adverse events to an infant patient with severe urea cycle disorder Athebody® DARPin-conjugated LNP resulted in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results